Cooper Companies (NASDAQ:COO) Trading Down 3.2% – Time to Sell?

Shares of The Cooper Companies, Inc. (NASDAQ:COO) traded down 3.2% during trading on Thursday . The stock traded as low as $53.15 and last traded at $52.8750. 419,036 shares traded hands during trading, a decline of 83% from the average session volume of 2,505,022 shares. The stock had previously closed at $54.61.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper Companies insiders showed confidence in the valuation through substantial purchases. Directors Paul Keel, Lawrence Kurzius and Walter Rosebrough Jr. collectively bought approximately $1.33 million of COO shares at prices around $53–$54 per share. These purchases could provide some support by signaling that insiders view the decline as excessive. Paul Keel insider purchase
• Positive Sentiment: The company’s $3 billion share-repurchase authorization, representing authorization to buy back up to roughly 22.7% of outstanding shares, may help support the stock and reflects management’s view that the shares are undervalued. However, buybacks may be less effective while earnings expectations remain under pressure.
• Neutral Sentiment: Multiple law firms, including Pomerantz, Bragar Eagel & Squire, Levi & Korsinsky and Kirby McInerney, have announced investigations into potential securities-law claims related to Cooper’s disclosures and the post-earnings selloff. These announcements add headline and potential litigation risk, but they do not establish wrongdoing. Pomerantz investigation
• Negative Sentiment: Third-quarter revenue of approximately $1.07 billion missed the $1.10 billion consensus estimate, despite adjusted EPS of $1.15 exceeding the $1.12 estimate. Investors focused on U.S. channel inventory reductions, which suggest distributors are destocking and could weigh on near-term sales. HBSS inventory report
• Negative Sentiment: Cooper lowered fiscal 2026 revenue guidance to approximately $4.23–$4.25 billion and adjusted EPS guidance to $4.51–$4.55, reflecting softer contact-lens demand, particularly at CooperVision. Analysts have also reduced the consensus price target to about $72.27, reinforcing concerns about slower growth.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Wall Street Zen lowered Cooper Companies from a “buy” rating to a “hold” rating in a research note on Saturday, September 12th. UBS Group dropped their target price on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating for the company in a report on Thursday, September 10th. Wells Fargo & Company set a $61.00 target price on shares of Cooper Companies and gave the company an “equal weight” rating in a research report on Thursday, September 10th. Weiss Ratings restated a “sell (d)” rating on shares of Cooper Companies in a research note on Friday, September 4th. Finally, Needham & Company LLC lowered their price target on shares of Cooper Companies from $86.00 to $73.00 and set a “buy” rating on the stock in a research report on Thursday, September 10th. Five equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $71.47.

Cooper Companies Stock Performance

The stock has a 50 day simple moving average of $70.58 and a 200 day simple moving average of $68.98. The stock has a market cap of $10.16 billion, a P/E ratio of 18.22, a price-to-earnings-growth ratio of 2.17 and a beta of 0.82. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. The business had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.Cooper Companies’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities analysts expect that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies announced that its board has authorized a stock repurchase program on Wednesday, September 9th that allows the company to buyback $3.00 billion in shares. This buyback authorization allows the medical device company to repurchase up to 22.7% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity at Cooper Companies

In related news, Director Paul Keel bought 4,701 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was purchased at an average price of $53.18 per share, with a total value of $249,999.18. Following the completion of the acquisition, the director owned 4,701 shares of the company’s stock, valued at $249,999.18. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Walter Rosebrough, Jr. bought 3,000 shares of the business’s stock in a transaction on Monday, September 14th. The stock was bought at an average price of $54.29 per share, for a total transaction of $162,870.00. Following the transaction, the director directly owned 20,000 shares of the company’s stock, valued at approximately $1,085,800. This represents a 17.65% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 24,701 shares of company stock valued at $1,330,739 over the last ninety days. 2.08% of the stock is owned by corporate insiders.

Institutional Trading of Cooper Companies

Several hedge funds and other institutional investors have recently made changes to their positions in the company. HBK Investments L P acquired a new position in shares of Cooper Companies in the second quarter valued at approximately $31,666,000. Sequoia Financial Advisors LLC increased its position in Cooper Companies by 290.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 34,286 shares of the medical device company’s stock valued at $2,459,000 after acquiring an additional 25,504 shares during the period. Tidal Investments LLC raised its stake in shares of Cooper Companies by 281.4% during the second quarter. Tidal Investments LLC now owns 82,903 shares of the medical device company’s stock valued at $5,945,000 after acquiring an additional 61,165 shares during the last quarter. National Pension Service lifted its holdings in Cooper Companies by 9,314.0% during the 2nd quarter. National Pension Service now owns 526,149 shares of the medical device company’s stock worth $37,730,000 after buying an additional 520,560 shares during the period. Finally, WINTON GROUP Ltd lifted its stake in shares of Cooper Companies by 379.0% in the second quarter. WINTON GROUP Ltd now owns 42,483 shares of the medical device company’s stock worth $3,046,000 after acquiring an additional 33,613 shares during the period. 24.39% of the stock is currently owned by institutional investors.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.